Literature DB >> 11025384

Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia.

C Silva1, M E Rio, F Cruz.   

Abstract

OBJECTIVES: To assess the pungency and the desensitizing effects of intravesical resiniferatoxin, an ultrapotent capsaicin analog, in patients with detrusor hyperreflexia.
METHODS: Fourteen patients with detrusor hyperreflexia were instilled during 30 min, without any form of local anesthesia, with 100 ml (or the bladder capacity if lower than that volume) of 50 or 100 nM resiniferatoxin solutions in 10% alcohol in saline. Patients were evaluated by voiding chart and urodynamic tests (volume to first contraction, maximal cystometric capacity, maximal detrusor pressure, icewater test) at 14, 30, 60, and 90 days and every 3 months thereafter
RESULTS: Resiniferatoxin instillation did not evoke pain or temporary worsening of urinary symptoms. Treatment improved or abolished incontinence in 9 out of 12 incontinent patients. Mean urinary frequency decreased from 14.2+/-6.4 to 10.3+/-3.2 at 3 months (p = 0.01). At this time point, mean maximal cystometric capacity increased from 182.3+/-119.8 to 330.0+/-201.6 ml (p = 0.01) and the ice water test, positive in 13 cases, became negative in 8 of them. Maximal detrusor pressure was not modified by the treatment. The effect was long-lasting, reaching 12 months in 7 cases.
CONCLUSIONS: The absence of irritative symptoms during bladder instillation of resiniferatoxin and the rapid onset of desensitization make this vanilloid superior to capsaicin for the treatment of detrusor hyperreflexia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025384     DOI: 10.1159/000020322

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

2.  Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC).

Authors:  Tony Y H Chen; Jacques Corcos; Michel Camel; Yves Ponsot; Le Mai Tu
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-04-08

Review 3.  Vanilloid receptor ligands: hopes and realities for the future.

Authors:  A Szallasi
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Resiniferatoxin in the treatment of interstitial cystitis: a systematic review.

Authors:  Eleni G Mourtzoukou; Christos Iavazzo; Matthew E Falagas
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-19

Review 5.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies.

Authors:  Ranan DasGupta; Clare J Fowler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Resiniferatoxin and tetrodotoxin induced NPY and TH immunoreactivity changes within the paracervical ganglion neurons supplying the urinary bladder.

Authors:  Piotr J Burliński; Anna M Burlińska; Sławomir Gonkowski; Jarosław Całka
Journal:  J Mol Neurosci       Date:  2012-10-02       Impact factor: 3.444

8.  Neurogenic bladder.

Authors:  Peter T Dorsher; Peter M McIntosh
Journal:  Adv Urol       Date:  2012-02-08

Review 9.  Intravesical therapy for overactive bladder.

Authors:  Robert J Evans
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

Review 10.  Current standard of care in treatment of bladder pain syndrome/interstitial cystitis.

Authors:  Sabela Rodriguez Lopez; Naşide Mangır
Journal:  Ther Adv Urol       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.